Cellectis (CLLS) Net Income towards Common Stockholders Growth (5y) (2020 - 2026)
Cellectis (CLLS) Net Income towards Common Stockholders Growth (5y) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Cellectis |
17.40 Bn |
17.21 Bn |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
5.74% |
| Dec 31, 2025 |
8.31% |
| Sep 30, 2025 |
15.09% |
| Jun 30, 2025 |
5.95% |
| Mar 31, 2025 |
-23.75% |
| Dec 31, 2024 |
16.64% |
| Sep 30, 2024 |
-7.58% |
| Jun 30, 2024 |
5.45% |
| Mar 31, 2024 |
18.84% |
| Dec 31, 2023 |
-12.62% |
| Sep 30, 2023 |
5.18% |
| Jun 30, 2023 |
-10.04% |
| Mar 31, 2023 |
-3.41% |
| Dec 31, 2022 |
0.26% |
| Sep 30, 2022 |
-1.71% |
| Jun 30, 2022 |
6.48% |
| Mar 31, 2022 |
-10.04% |
| Dec 31, 2021 |
-13.19% |
| Sep 30, 2021 |
-21.63% |
| Jun 30, 2021 |
-41.38% |
